Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Airway Obstruction D000402 13 associated lipids
Uremia D014511 33 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypoxia D000860 23 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Ovarian Neoplasms D010051 10 associated lipids
Pain D010146 64 associated lipids
Contusions D003288 3 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Wounds and Injuries D014947 20 associated lipids
Pleurisy D010998 20 associated lipids
Burns D002056 34 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Tanaka H et al. Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. 1999 Allergy pmid:10380781
Elissalde MH and Beier RC Stimulation and release of prostaglandins and thromboxane from macrophages by cotton dust associated lipopolysaccharides. 1990 Am Ind Hyg Assoc J pmid:2270833
Andersson T et al. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. 2012 Am J Cardiovasc Drugs pmid:22631032
Leese PT et al. Valdecoxib does not impair platelet function. 2002 Am J Emerg Med pmid:12098171
Jung TT and Juhn SK Prostaglandins in human cholesteatoma and granulation tissue. 1988 Am J Otol pmid:3177602
Mehta P et al. Plasma concentrations of thromboxane and prostacyclin metabolites in patients with bone tumors. 1985 Am J Pediatr Hematol Oncol pmid:2994511
Natarajan G et al. Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants. 2008 Am J Perinatol pmid:18726836
Brown HL et al. Plasma and amniotic fluid prostacyclin and thromboxane in mild pregnancy-induced hypertension. 1987 Am J Perinatol pmid:3566883
Satterfield S et al. Biochemical markers of compliance in the Physicians' Health Study. 1990 Sep-Oct Am J Prev Med pmid:2268456
Ingster LM and Feinleib M Salicylate intake and cardiovascular disease: Ingster and Feinleib respond to Hu and Willett. 1998 Am J Public Health pmid:9702172
Cambria RA et al. Thromboxane synthetase inhibition decreases polymorphonuclear leukocyte activation following hindlimb ischemia. 1991 Am Surg pmid:1847027
Montalescot G et al. Early thromboxane release during pacing-induced myocardial ischemia with angiographically normal coronary arteries. 1990 Am. Heart J. pmid:2248190
Hirsh PD et al. Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. 1982 Am. Heart J. pmid:7102506
Smith EF and Lefer AM Stabilization of cardiac lysosomal and cellular membranes in protection of ischemic myocardium due to coronary occlusion:efficacy of the nonsteroidal anti-inflammatory agent, naproxen. 1981 Am. Heart J. pmid:7211667
Nakashima Y et al. Sustained-release nifedipine (nifedipine-L) suppresses plasma thromboxane B2 and 6-keto prostaglandin F1 alpha in both young male smokers and nonsmokers. 1990 Am. Heart J. pmid:2353613
Ikonomidis I et al. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. 2005 Am. Heart J. pmid:15894964
Kishi Y et al. Inhibition of platelet aggregation by prostacyclin is attenuated after exercise in patients with angina pectoris. 1992 Am. Heart J. pmid:1736562
Tomoda H Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). 1986 Am. Heart J. pmid:3532743
Nitz RE and Martorana PA The activity of molsidomine in experimental models of ischemic cardiac disease. 1985 Am. Heart J. pmid:3919549
Buchanan MR et al. Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease. 1987 Am. Heart J. pmid:2953219
Walinsky P et al. Thromboxane A2 in acute myocardial infarction. 1984 Am. Heart J. pmid:6485997
Rubenstein MD et al. Platelet activation in clinical coronary artery disease and spasm. 1981 Am. Heart J. pmid:6455912
De Caterina R et al. Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects. 1990 Am. Heart J. pmid:2321506
Lorenzoni R et al. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. 2004 Am. Heart J. pmid:15215815
Buerke M et al. Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. 1995 Am. Heart J. pmid:7661062
Mehta J et al. Thromboxane release in coronary artery disease: spontaneous versus pacing-induced angina. 1984 Am. Heart J. pmid:6695662
De Servi S et al. Coronary vasoconstrictor response to cold pressor test in variant angina: lack of relation to intracoronary thromboxane concentrations. 1987 Am. Heart J. pmid:3630891
Cotter G et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? 2004 Am. Heart J. pmid:14760328
Mehta J and Mehta P Prostacyclin and thromboxane A2 production by human cardiac atrial tissues. 1985 Am. Heart J. pmid:3880988
Friedrich T et al. Follow-up of prostaglandin plasma levels after acute myocardial infarction. 1985 Am. Heart J. pmid:3880994
O'Connor KM et al. The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models. 1989 Am. Heart J. pmid:2929400
Zhu BQ and Parmley WW Modification of experimental and clinical atherosclerosis by dietary fish oil. 1990 Am. Heart J. pmid:2105047
Neri Serneri GG et al. Abnormal cardiocoronary thromboxane A2 production in patients with unstable angina. 1985 Am. Heart J. pmid:3984828
O'Connor KM et al. Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. 1986 Am. Heart J. pmid:3953390
Roy L et al. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease. 1985 Am. Heart J. pmid:3158183
Austin JC et al. Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion. 1988 Am. Heart J. pmid:3344655
Yamada Y et al. Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator. 1991 Am. Heart J. pmid:1903579
Arora RR et al. Laser-induced stimulation of thromboxane B2 synthesis in human blood platelets: role of superoxide radicals. 1993 Am. Heart J. pmid:8381256
FitzGerald GA et al. Cigarette smoking and hemostatic function. 1988 Am. Heart J. pmid:3276116
Jouve R et al. Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy. 1984 Am. Heart J. pmid:6581715
Rebuzzi AG et al. Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. 1992 Am. Heart J. pmid:1539506
Catella-Lawson F et al. Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. 2001 Am. J. Cardiol. pmid:11472700
Hanet C et al. Myocardial protection by intracoronary nicardipine administration during percutaneous transluminal coronary angioplasty. 1987 Am. J. Cardiol. pmid:2953226
McDaniel HG et al. Platelet function abnormalities in response to arachidonic acid in the acute phase of myocardial infarction. 1983 Am. J. Cardiol. pmid:6416046
De Caterina R et al. Inhibition of platelet function by injectable isosorbide dinitrate. 1984 Am. J. Cardiol. pmid:6428211
Eldar M et al. Bradykinin level in the great cardiac vein during balloon angioplasty of the left anterior descending coronary artery. 1992 Am. J. Cardiol. pmid:1466338
Dabaghi SF et al. Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. 1994 Am. J. Cardiol. pmid:7942533
Théroux P et al. Hemodynamic, platelet and clinical responses to prostacyclin in unstable angina pectoris. 1990 Am. J. Cardiol. pmid:2109927
Willerson JT et al. Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. 1984 Am. J. Cardiol. pmid:6391133
Shen H et al. Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). 2009 Am. J. Cardiol. pmid:19660620